Acute Myeloid Leukemia | China In-Depth | China | 2022
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, the treatment of AML in China is managed with chemotherapy; however, the approvals of Celgene’s Vidaza (azacitidine) in 2017, Venclexta (venetoclax) and Xospata (gilteritinib) in 2021, and the expected approvals of several therapies available in Western markets during the forecast period will transform the AML treatment landscape in China. The entry of novel agents into the treatment paradigm will enable increasingly personalized treatment, but several areas of unmet need will remain. Most notably, significant commercial opportunity will exist for innovative agents to treat relapsed / refractory AML patients and those unfit for intensive chemotherapy induction. Additionally, with the ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies are increasingly incentivized to enter the Chinese market.
QUESTIONS ANSWERED
- How large is China’s drug-treatable AML population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s AML market and why? What are interviewed experts’ insights into current treatment options?
- What are the market access considerations for key therapies in the AML pipeline in China? What sales could these agents secure in AML? What are interviewed experts’ opinions of key emerging therapies?
- What are the key drivers and constraints in China’s AML therapy market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Release date
April 2022
Geographies
China
Primary Research
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 hematologist-oncologists.
Epidemiology
Diagnosed incidence of AML in urban versus rural China, clinically relevant and market-relevant drug-treatable populations.
FORECAST
10-year, annualized, drug-level sales and patient share of key AML therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.
EMERGING THERAPIES
Phase III: 6 drugs. Phase I/II: 10+ drugs. Coverage of select early-phase products.
